Stock ADCT ADC THERAPEUTICS SA
Add to a list
To use this feature you must be a member
Log inSign up

Company ADC Therapeutics SA

Equities

ADCT

CH0499880968

Biotechnology & Medical Research

Delayed Nyse
Other stock markets
 20:56:56 02/05/2024 BST 		5-day change 1st Jan Change
4.72 USD +0.21% Intraday chart for ADC Therapeutics SA +6.76% +185.54%
04-09 Transcript : ADC Therapeutics SA - Special Call
04-04 Sector Update: Health Care Stocks Slump Late Afternoon MT

Business Summary

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Number of employees: 274

Sales per Business

USD in Million2022Weight2023Weight Delta
Antibody Drug Conjugates
100.0 %
210 100.0 % 70 100.0 % -66.86%

Managers

Managers TitleAgeSince
Ameet Mallik CEO
 Chief Executive Officer 51 08/05/22
Jose Carmona DFI
 Director of Finance/CFO 51 18/12/22
Mohamed Zaki CTO
 Chief Tech/Sci/R&D Officer 59 02/01/23
Patrick van Berkel CTO
 Chief Tech/Sci/R&D Officer 55 31/07/12
Michael Mulkerrin CTO
 Chief Tech/Sci/R&D Officer 69 31/10/22
Kristen Harrington-Smith PRN
 Corporate Officer/Principal 51 16/11/22
Kimberly Pope HRO
 Human Resources Officer 57 16/08/20
Peter J. Graham LAW
 General Counsel 57 31/10/22

Members of the board

Members of the board TitleAgeSince
Peter Hug BRD
 Director/Board Member 65 31/05/19
Ron Squarer CHM
 Chairman 57 31/03/20
Jean Bizzari BRD
 Director/Board Member 69 30/06/22
Ameet Mallik CEO
 Chief Executive Officer 51 08/05/22
Victor Sandor BRD
 Director/Board Member 57 26/04/20
Robert Azelby BRD
 Director/Board Member 56 13/06/23
Thomas Pfisterer BRD
 Director/Board Member 42 30/09/16
Tyrell J. Rivers BRD
 Director/Board Member 51 31/05/18
Viviane Monges BRD
 Director/Board Member 60 10/06/21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 89,562,809 62,947,767 ( 70.28 %) 6,748,809 ( 7.535 %) 70.28 %

Shareholders

NameEquities%Valuation
Redmile Group LLC
18.57 %
15,328,317 18.57 % 69 M $
Thomas Pfisterer
11.86 %
9,788,944 11.86 % 44 M $
Prosight Management LP
7.842 %
6,471,800 7.842 % 29 M $
ASTRAZENECA PLC
4.860 %
4,011,215 4.860 % 18 M $
Millennium Management LLC
3.239 %
2,672,810 3.239 % 12 M $
Auven Therapeutics Management LLLP
2.733 %
2,255,719 2.733 % 10 M $
Christopher Martin
2.386 %
1,968,743 2.386 % 9 M $
Citadel Securities GP LLC
2.246 %
1,853,412 2.246 % 8 M $
Ron Squarer
1.864 %
1,538,432 1.864 % 7 M $
Bank of America, NA (Charlotte, North Carolina)
1.849 %
1,525,741 1.849 % 7 M $

Company contact information

ADC Therapeutics SA

Biopôle Route de la Corniche 3B

1066, Epalinges

+

http://www.adctherapeutics.com
address ADC Therapeutics SA(ADCT)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for ADC Therapeutics SA

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.71 USD
Average target price
10.2 USD
Spread / Average Target
+116.56%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ADC THERAPEUTICS SA Stock ADC Therapeutics SA
+185.54% 390M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.75% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+6.78% 97.47B
ARGENX SE Stock argenx SE
+5.71% 22.25B
BIONTECH SE Stock BioNTech SE
-12.89% 21.68B
GENMAB A/S Stock Genmab A/S
-9.70% 18.2B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.02B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.25% 16.36B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.51% 14.39B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.21% 12.37B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ADCT Stock
  4. Company ADC Therapeutics SA